Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 2 Pre-treatment evaluation among HCV treated at the Stockholm NSP (n = 162)

From: Real-world hepatitis C treatment outcomes and reinfections among people who inject drugs at a needle and syringe program in Stockholm, Sweden

Genotype

n = 162 (%)

 1a

62 (38.3)

 1b

5 (3.1)

 2

25 (15.4)

 3a

70 (43.2)

Fibrosis score

n = 158

 Mean (SD) kPa

7.5 (4.0)

 Median (range) kPa

6.3 (3.4–33.8)

Fibrosis stages (kPa)

n = 158 (%)

 F0-F1 (< 7)

91 (57.6)

 F2 (7–9.4)

38 (24.1)

 F3 (9.5–12.4)

17 (10.8)

 F4 (≥ 12.5)

12 (7.6)

APRI score

n = 152

 Mean (SD)

0.5 (0.4)

 Median (range)

0.4 (0.09—2.3)

DAA treatment

n = 162 (%)

 Glecaprevir + Pibrentasvir

64 (39.5)

 Sofosbuvir + Ledispavir

61 (37.7)

 Sofosbuvir + Velpatasvir

36 (22.2)

 Elbasvir + Grazoprevir

1 (0.6)